[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100567583":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":19,"locations":25,"responsibleParty":42,"collaborators":11,"id":45,"slug":11,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":11,"eligibilityCriteria":49,"healthyVolunteers":46,"sex":50,"minAge":51,"maxAge":11,"enrollmentInfo":52,"targetDuration":11,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":11,"overallStatus":27,"whyStopped":11,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},{"fullName":5,"class":6},"University of Vermont","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Prolonged exposure therapy + incentives for therapy session attendance","EXPERIMENTAL",null,[13],"Behavioral: Prolonged exposure therapy + incentives for therapy session attendance",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":11},"BEHAVIORAL","Prolonged exposure therapy plus incentives for therapy session attendance",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":11,"email":24},"Kelly Peck, PhD","CONTACT","802-656-9610","kelly.peck@uvm.edu",[26],{"facility":5,"status":27,"city":28,"state":29,"zip":30,"country":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"RECRUITING","Burlington","Vermont","05401","United States",{"type":33,"coordinates":34},"Point",[35,36],-73.21207,44.47588,{"lat":36,"lon":35},[39],{"name":40,"role":22,"phone":41,"phoneExt":11,"email":24},"Kelly Peck","8026569610",{"type":43,"investigatorFullName":40,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Professor","100567583",false,"NCT06670079","Prolonged Exposure Therapy to Treat Posttraumatic Stress Disorder in Pregnant Patients","Inclusion Criteria:\n\n* Female\n* \\>18 years old\n* Gestational age ≤ 25 weeks\n* Meet current DSM-5 posttraumatic stress disorder criteria based on the Clinician Administered PTSD Scale for DSM-5\n* Participants receiving psychotropic medications must be maintained on a stable dose for \\>14 days prior to enrollment.\n\nExclusion Criteria:\n\n* Male\n* Under 18 years old\n* Gestational age \\> 25 weeks\n* No current diagnosis of PTSD\n* Current delusions or hallucinations, unstable bipolar disorder, imminent risk for suicide as assessed by the Mini International Neuropsychiatric Interview\n* Enrolled in another ongoing evidence-based treatment for PTSD.","FEMALE","18 Years",{"count":53,"type":54},30,"ESTIMATED","INTERVENTIONAL",[57],"NA","The goal of this clinical trial is to learn if a treatment for adults with PTSD called prolonged exposure + incentives (PE+) works to treat pregnant patients. The main question it aims to answer is:\n\nDoes PE+ decrease PTSD symptoms?\n\nAll participants will receive PE+ to see if their PTSD symptoms at the end of the trial are less than at the beginning.\n\nParticipants will:\n\n* Receive individual PE+ therapy for 1 hour weekly for 12 weeks.\n* Receive financial incentives for attending each PE+ session.\n* Attend assessment visits every 4 weeks for the 12 weeks of the trial.\n* Allow research staff to collect some information about their labor and delivery from their medical records after their babies are born.",[60,61],"Posttraumatic Stress Disorder","Pregnancy","2026-05-08",{"date":64,"type":65},"2026-05-13","ACTUAL",{"date":67,"type":65},"2026-02-05",{"date":69,"type":54},"2027-07-22",{"name":5,"class":6},1]